445 related articles for article (PubMed ID: 17904541)
1. Effects of anticoagulants on the activity of gelatinases.
Castellazzi M; Tamborino C; Fainardi E; Manfrinato MC; Granieri E; Dallocchio F; Bellini T
Clin Biochem; 2007 Nov; 40(16-17):1272-6. PubMed ID: 17904541
[TBL] [Abstract][Full Text] [Related]
2. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
Gerlach RF; Demacq C; Jung K; Tanus-Santos JE
Clin Biochem; 2007 Jan; 40(1-2):119-23. PubMed ID: 17150202
[TBL] [Abstract][Full Text] [Related]
3. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.
Gerlach RF; Uzuelli JA; Souza-Tarla CD; Tanus-Santos JE
Anal Biochem; 2005 Sep; 344(1):147-9. PubMed ID: 15950912
[No Abstract] [Full Text] [Related]
4. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.
Mannello F; Tanus-Santos JE; Meschiari CA; Tonti GA
Anal Biochem; 2008 Mar; 374(1):56-63. PubMed ID: 18082127
[TBL] [Abstract][Full Text] [Related]
5. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls.
Rababah M; Worthmann H; Deb M; Tryc AB; Ma YT; El Bendary OM; Hecker H; Goldbecker A; Heeren M; Brand K; Weissenborn K; Lichtinghagen R
Clin Biochem; 2012 Apr; 45(6):483-9. PubMed ID: 22342361
[TBL] [Abstract][Full Text] [Related]
7. [Complement activation in citrate plasma--inhibitory effect of anticoagulants on serum complement activation].
Kobayashi E; Kitano E; Kondo H; Kitamura H
Rinsho Byori; 1999 Feb; 47(2):160-4. PubMed ID: 10097633
[TBL] [Abstract][Full Text] [Related]
8. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Mannello F; Jung K; Tonti GA; Canestrari F
Clin Biochem; 2008 Dec; 41(18):1466-73. PubMed ID: 18926810
[TBL] [Abstract][Full Text] [Related]
9. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum.
Scheffer PG; van der Zwan LP; Schindhelm RK; Vermue HP; Teerlink T
Clin Biochem; 2009 Sep; 42(13-14):1490-2. PubMed ID: 19524564
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.
Peake NJ; Foster HE; Khawaja K; Cawston TE; Rowan AD
Ann Rheum Dis; 2006 Apr; 65(4):501-7. PubMed ID: 16150790
[TBL] [Abstract][Full Text] [Related]
11. Use of different anticoagulants in test tubes for analysis of blood lactate concentrations: Part 2. Implications for the proper handling of blood specimens obtained from critically ill patients.
Wiese J; Didwania A; Kerzner R; Chernow B
Crit Care Med; 1997 Nov; 25(11):1847-50. PubMed ID: 9366768
[TBL] [Abstract][Full Text] [Related]
12. [Effect of anticoagulants on the activity of trypsin-like proteinases in human blood plasma].
Babiĭ AV; Sakharov IIu; Pokrovskiĭ SN
Biull Eksp Biol Med; 1989 Feb; 107(2):177-9. PubMed ID: 2538168
[TBL] [Abstract][Full Text] [Related]
13. Effects of heparin, citrate, and EDTA on plasma biochemistry of sheep: comparison with serum.
Mohri M; Rezapoor H
Res Vet Sci; 2009 Feb; 86(1):111-4. PubMed ID: 18572209
[TBL] [Abstract][Full Text] [Related]
14. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.
Jung K; Laube C; Lein M; Lichtinghagen R; Tschesche H; Schnorr D; Loening SA
Clin Chem; 1998 May; 44(5):1060-2. PubMed ID: 9590387
[No Abstract] [Full Text] [Related]
15. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
16. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.
Mollnes TE; Garred P; Bergseth G
Clin Exp Immunol; 1988 Sep; 73(3):484-8. PubMed ID: 2463123
[TBL] [Abstract][Full Text] [Related]
17. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display.
Tammen H; Schulte I; Hess R; Menzel C; Kellmann M; Mohring T; Schulz-Knappe P
Proteomics; 2005 Aug; 5(13):3414-22. PubMed ID: 16038021
[TBL] [Abstract][Full Text] [Related]
18. Measurement of Elecsys NT-proBNP in serum, K2 EDTA and heparin plasma.
Lippi G; Salvagno GL; Montagnana M; Guidi GC
Clin Biochem; 2007 Jun; 40(9-10):747-8. PubMed ID: 17408609
[TBL] [Abstract][Full Text] [Related]
19. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.
Souza-Tarla CD; Uzuelli JA; Machado AA; Gerlach RF; Tanus-Santos JE
Clin Biochem; 2005 May; 38(5):410-4. PubMed ID: 15820769
[TBL] [Abstract][Full Text] [Related]
20. Influence of pre-analytical and analytical factors on soluble CD40L measurements.
Varo N; Nuzzo R; Natal C; Libby P; Schönbeck U
Clin Sci (Lond); 2006 Nov; 111(5):341-7. PubMed ID: 16856875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
